Log in

NASDAQ:MNOV - MediciNova Stock Price, Forecast & News

$7.53
-0.20 (-2.59 %)
(As of 12/16/2019 07:48 AM ET)
Today's Range
$7.48
Now: $7.53
$7.73
50-Day Range
$7.00
MA: $7.71
$8.72
52-Week Range
$6.68
Now: $7.53
$13.37
Volume48,800 shs
Average Volume101,742 shs
Market Capitalization$330.12 million
P/E RatioN/A
Dividend YieldN/A
Beta1.2
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MNOV
CUSIPN/A
Phone858-373-1500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.75 per share

Profitability

Net Income$-14,670,000.00

Miscellaneous

Employees9
Market Cap$330.12 million
Next Earnings Date2/12/2020 (Estimated)
OptionableOptionable

Receive MNOV News and Ratings via Email

Sign-up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter.


MediciNova (NASDAQ:MNOV) Frequently Asked Questions

What is MediciNova's stock symbol?

MediciNova trades on the NASDAQ under the ticker symbol "MNOV."

How were MediciNova's earnings last quarter?

MediciNova, Inc. (NASDAQ:MNOV) released its quarterly earnings results on Friday, October, 25th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.15) by $0.10. View MediciNova's Earnings History.

When is MediciNova's next earnings date?

MediciNova is scheduled to release their next quarterly earnings announcement on Wednesday, February 12th 2020. View Earnings Estimates for MediciNova.

What price target have analysts set for MNOV?

1 brokerages have issued 1 year price objectives for MediciNova's shares. Their forecasts range from $22.00 to $22.00. On average, they expect MediciNova's stock price to reach $22.00 in the next year. This suggests a possible upside of 192.2% from the stock's current price. View Analyst Price Targets for MediciNova.

What is the consensus analysts' recommendation for MediciNova?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediciNova in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MediciNova.

Has MediciNova been receiving favorable news coverage?

News headlines about MNOV stock have trended somewhat negative on Monday, InfoTrie reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. MediciNova earned a media sentiment score of -1.7 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for MediciNova.

Who are some of MediciNova's key competitors?

What other stocks do shareholders of MediciNova own?

Who are MediciNova's key executives?

MediciNova's management team includes the folowing people:
  • Dr. Yuichi Iwaki, Co-Founder, Pres, CEO & Exec. Director (Age 69)
  • Mr. Masatsune Okajima, Head of Japanese Office & VP (Age 51)
  • Dr. Kazuko Matsuda M.P.H., M.D., Ph.D., MPH, Chief Medical Officer (Age 53)
  • Ms. Carla Reyes, Chief Financial Officer (Age 47)
  • Mr. John O'Neil CPA, Controller

Who are MediciNova's major shareholders?

MediciNova's stock is owned by many different of retail and institutional investors. Top institutional shareholders include State Street Corp (1.69%), Alps Advisors Inc. (0.20%), California Public Employees Retirement System (0.13%), Squarepoint Ops LLC (0.07%), Barclays PLC (0.05%) and Tower Research Capital LLC TRC (0.01%). View Institutional Ownership Trends for MediciNova.

Which institutional investors are selling MediciNova stock?

MNOV stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, Alps Advisors Inc. and Tower Research Capital LLC TRC. View Insider Buying and Selling for MediciNova.

Which institutional investors are buying MediciNova stock?

MNOV stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Squarepoint Ops LLC and California Public Employees Retirement System. View Insider Buying and Selling for MediciNova.

How do I buy shares of MediciNova?

Shares of MNOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is MediciNova's stock price today?

One share of MNOV stock can currently be purchased for approximately $7.53.

How big of a company is MediciNova?

MediciNova has a market capitalization of $330.12 million. The biopharmaceutical company earns $-14,670,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. MediciNova employs 9 workers across the globe.View Additional Information About MediciNova.

What is MediciNova's official website?

The official website for MediciNova is http://medicinova.com/.

How can I contact MediciNova?

MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-373-1500 or via email at [email protected]


MarketBeat Community Rating for MediciNova (NASDAQ MNOV)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  180 (Vote Outperform)
Underperform Votes:  151 (Vote Underperform)
Total Votes:  331
MarketBeat's community ratings are surveys of what our community members think about MediciNova and other stocks. Vote "Outperform" if you believe MNOV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNOV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel